Literature DB >> 8958808

Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications.

E T Ruijter1, C A van de Kaa, J A Schalken, F M Debruyne, D J Ruiter.   

Abstract

In order to understand the clinical and biological implications of prostate cancer multifocality and heterogeneity, we investigated their occurrence in relation to variables such as tumour volume, local invasion, and biopsy findings. In a series of 61 completely sectioned whole-mount radical prostatectomy specimens with clinical stage T2 prostate cancer, we mapped histological grade heterogeneity and tumour multifocality. We also evaluated 55 prostate biopsy cases to assess the accuracy of pre-operative grading. Among all of the prostates, only 28 per cent had a single tumour and in 16 per cent one histological grade of cancer was evident. Extracapsular invasion was not restricted to the largest tumour in each case, but also occurred in tumours of relatively small volume and low histological grade. Variability of histological grade was directly proportional to tumour volume. Both grade heterogeneity and tumour multifocality of the prostatectomy specimen showed no significant relationship to the grade accuracy of biopsies. Biopsy grading error proved greatest among small, well-differentiated, tumours. Whole-mount sectioning of prostatectomy specimens in patients with clinically localized adenocarcinoma demonstrates that grade heterogeneity is most closely related to tumour volume; that the largest (index) tumour lesion may not be representative of the pathological stage; and that grading error in prostate needle biopsies can be only partly explained by grade heterogeneity or tumour multifocality.

Entities:  

Mesh:

Year:  1996        PMID: 8958808     DOI: 10.1002/(SICI)1096-9896(199611)180:3<295::AID-PATH663>3.0.CO;2-W

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  53 in total

Review 1.  Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.

Authors:  Takeshi Sasaki; Omar E Franco; Simon W Hayward
Journal:  Differentiation       Date:  2017-07-20       Impact factor: 3.880

Review 2.  What is the pathologist saying? Interpretation of the prostate pathology report.

Authors:  Omar Hameed
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

3.  Spatial genomic heterogeneity within localized, multifocal prostate cancer.

Authors:  Paul C Boutros; Michael Fraser; Nicholas J Harding; Richard de Borja; Dominique Trudel; Emilie Lalonde; Alice Meng; Pablo H Hennings-Yeomans; Andrew McPherson; Veronica Y Sabelnykova; Amin Zia; Natalie S Fox; Julie Livingstone; Yu-Jia Shiah; Jianxin Wang; Timothy A Beck; Cherry L Have; Taryne Chong; Michelle Sam; Jeremy Johns; Lee Timms; Nicholas Buchner; Ada Wong; John D Watson; Trent T Simmons; Christine P'ng; Gaetano Zafarana; Francis Nguyen; Xuemei Luo; Kenneth C Chu; Stephenie D Prokopec; Jenna Sykes; Alan Dal Pra; Alejandro Berlin; Andrew Brown; Michelle A Chan-Seng-Yue; Fouad Yousif; Robert E Denroche; Lauren C Chong; Gregory M Chen; Esther Jung; Clement Fung; Maud H W Starmans; Hanbo Chen; Shaylan K Govind; James Hawley; Alister D'Costa; Melania Pintilie; Daryl Waggott; Faraz Hach; Philippe Lambin; Lakshmi B Muthuswamy; Colin Cooper; Rosalind Eeles; David Neal; Bernard Tetu; Cenk Sahinalp; Lincoln D Stein; Neil Fleshner; Sohrab P Shah; Colin C Collins; Thomas J Hudson; John D McPherson; Theodorus van der Kwast; Robert G Bristow
Journal:  Nat Genet       Date:  2015-05-25       Impact factor: 38.330

Review 4.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

5.  ERG rearrangement metastasis patterns in locally advanced prostate cancer.

Authors:  Sven Perner; Maria A Svensson; Ruhella R Hossain; John R Day; Jack Groskopf; Ryan C Slaughter; Analee R Jarleborn; Matthias D Hofer; Rainer Kuefer; Francesca Demichelis; David S Rickman; Mark A Rubin
Journal:  Urology       Date:  2010-04       Impact factor: 2.649

Review 6.  [Focal prostate cancer therapy: capabilities, limitations and prospects].

Authors:  D Baumunk; A Blana; R Ganzer; T Henkel; J Köllermann; A Roosen; S Machtens; G Salomon; L Sentker; U Witzsch; K U Köhrmann; M Schostak
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

Review 7.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

8.  Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.

Authors:  Lei Wei; Jianmin Wang; Erika Lampert; Simon Schlanger; Adam D DePriest; Qiang Hu; Eduardo Cortes Gomez; Mitsuko Murakam; Sean T Glenn; Jeffrey Conroy; Carl Morrison; Gissou Azabdaftari; James L Mohler; Song Liu; Hannelore V Heemers
Journal:  Eur Urol       Date:  2016-07-21       Impact factor: 20.096

9.  Prostate cancer epigenetics: a review on gene regulation.

Authors:  Lena Diaw; Karen Woodson; John W Gillespie
Journal:  Gene Regul Syst Bio       Date:  2007-12-11

10.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.